Followers | 26 |
Posts | 429 |
Boards Moderated | 0 |
Alias Born | 05/31/2015 |
Saturday, April 28, 2018 7:42:13 PM
5 year survival is not the same as the tail.
The tail is the benefit of immunotherapy
The classic example of that is Yervoy. It has a tail of about 10%.with melanoma. That is why it is approved. One of my specialties is operative managment of metastatic melanoma.
There is no tail in any approved treatment for glioblastoma period. No matter how many treatments someone gets(multiple surgeries or drugs) there is no tail. If you followed a hundred patients for a full 5 years 5-10% would be alive. Again that is different than 5 year survival on a KM curve. Neurosurgeons know that. My uncle is a neurosurgeon at Henry Ford Hospital and my best friend is a neurosurgeon at University of Washington. They can’t wait to see results. They believe in it.
If there is a blended tail above 20% this is gonna be a grandslam. I think once unblended the MOS of the treatment arm will be impressive anyways.
The publication is just a taste. It is with not fully mature data.
Wait until they hopefully update the blended data
If over 80 patients are alive, wow
I don’t really care what anyone else says. This is for people who know me. I never read this board anymore because of the ridiculous statements by a lot of people who are either lying or think they know what they are talking about when it comes to the science.
I am 100% confident we get approved.
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM